SCHEMBL2279268

SCHEMBL2279268

Cc1cc(OCc2ccccc2)c(C(=O)C=Cc2cccc(OCC(=O)O)c2)c(=O)n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
PKM P14618 2/20 0.51
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
POLB P06746 3/20 0.48
CYSLTR2 Q9NS75 2/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
THRB P10828 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
BCHE P06276 1/20 0.44
SLC5A1 P13866 1/20 0.42
SLC5A2 P31639 1/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279266 1.00 KDM4E (0.51) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2281414 0.93 CYSLTR2 (0.48) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2281410 0.93 CYSLTR2 (0.48) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2282707 0.92 ALDH1A1 (0.48) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2282703 0.92 ALDH1A1 (0.48) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2278507 0.89 ABCG2 (0.50) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL2278509 0.89 ABCG2 (0.50) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL2282843 0.88 CYSLTR2 (0.45) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2282848 0.88 CYSLTR2 (0.45) KDM4EALDH1A1PKMMEN1KMT2A
SCHEMBL2283908 0.85 ABCG2 (0.47) KDM4EALDH1A1MEN1KMT2ACYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 KDM4E 2443/4885ALDH1A1 576/4885PKM 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.